Key result
Prenatal therapy for fetal cardiac disorders ranges from maternal administration of drugs for transplacental transfer to invasive fetal cardiac intervention.
Why the study?
What are the available prenatal therapeutic options for fetal cardiac disorders?
What are the available prenatal therapeutic options for fetal cardiac disorders?
This review provides a comprehensive overview of prenatal therapeutic options for fetal cardiac disorders, highlighting the need for intervention to reduce high morbidity and mortality rates.
Answers are grounded in this paper and cite their sources.
Optimal fetal cardiac therapy strategies remain undefined; leaves open need for prospective trials before guiding prenatal care.
Fetal cardiac abnormalities are some of the commonest congenital disorders seen in prenatal life. They can be anatomical or functional and can develop de novo or as a consequence of either maternal or fetal disease. Untreated, morbidity and mortality rates are high for hypoplastic left heart disorders and for some fetal tachy and bradyarrhythmias. Optimum management strategies are often not clear because of the lack of knowledge about the precise natural history of some of these conditions. Prenatal therapy ranges from invasive fetal cardiac intervention to maternal administration of drugs for transplacental transfer to the fetus. This comprehensive review covers many fetal cardiac disorders and various prenatal therapeutic options that are available.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2018) conducted a review in Fetal cardiac disorders. Prenatal therapy was evaluated. Prenatal therapy for fetal cardiac disorders ranges from maternal administration of drugs for transplacental transfer to invasive fetal cardiac intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: